相关实验视频
Updated: Sep 15, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
357
抗肥胖药物治疗中的新型口服药物:叙事性审查
Assaf Buch1,2, Roy Eldor2,3, Roy Brown2
1Department of Nutrition Sciences, School of Health Sciences, Ariel University, Ariel, Israel.
Diabetes, obesity & metabolism
|July 15, 2025
概括
新型口服抗肥胖药物在体重管理方面表现有前途. 这些新兴疗法可能为注射药提供替代品,改善患者获得和长期肥胖护理的坚持.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 肥胖是一个关键的全球健康问题,具有重大的医疗和经济影响.
- 注射药物如西马格卢提德和蒂尔泽帕提德是有效的,但有局限性.
- 新的口服抗肥胖药物提供了潜在的治疗进展.
研究的目的:
- 审查肥胖的口服药物治疗的最新进展.
- 检查新兴口服药物的作用机制,临床有效性和安全性概况.
- 将口服疗法在全面肥胖管理中的作用置于背景.
主要方法:
- 在PubMed,科克伦图书馆,谷歌学者和clinicaltrials.gov.gov的系统文献搜索.
- 包括2023年1月至2025年6月期间发表的研究.
- 专注于正在接受临床评估的新兴口服化合物,包括口服GLP-1RA,,小分子和非因克雷丁基疗法.
主要成果:
- 几种新兴的口服药物表现出有希望的疗效,在临床试验中达到≥10%的体重减轻.
- 这些药物通常表现出有利的安全性.
- 新兴的口服疗法有潜力补充或取代长期体重管理的注射疗法.
结论:
- 口服药物治疗对解决全球肥胖流行病具有重大前景.
- 新兴的口服药物可能会提高患者的获取,坚持和满意度.
- 进一步的研究至关重要,以确认全面的肥胖护理的长期安全性和有效性.
关键词:
作为GLP-1受体的激动剂.抗肥胖药物治疗药物治疗.胃抑制性多,是一种胃抑制性多.类似于葡萄糖的-1-1肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖服用口服抗糖尿病药物的药物.酸是一种酸.受体激动剂的受体激动剂.小分子的小分子.减肥 减肥 减肥 减肥 减肥 减肥更多相关视频
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
267
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
267
Oral Hypoglycemic Agents: Biguanides and Glitazones
306
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
306
Oral Hypoglycemic Agents: Glinides
268
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
268
Oral Hypoglycemic Agents: Sulfonylureas
345
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
345
Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
Obesity
622
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
622

